Bausch + Lomb (NYSE:BLCO) EVP A Robert Bailey Buys 14,600 Shares

Bausch + Lomb Corporation (NYSE:BLCO) EVP A Robert Bailey purchased 14,600 shares of the business’s stock in a transaction on Friday, March 6th. The shares were bought at an average cost of $17.15 per share, for a total transaction of $250,390.00. Following the purchase, the executive vice president owned 231,890 shares of the company’s stock, valued at $3,976,913.50. This trade represents a 6.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Bausch + Lomb Stock Down 0.6%

Shares of BLCO opened at $17.12 on Wednesday. Bausch + Lomb Corporation has a fifty-two week low of $10.45 and a fifty-two week high of $18.92. The company’s fifty day moving average is $17.28 and its two-hundred day moving average is $16.18. The firm has a market cap of $6.06 billion, a PE ratio of -16.78, a price-to-earnings-growth ratio of 0.73 and a beta of 0.58. The company has a quick ratio of 1.04, a current ratio of 1.55 and a debt-to-equity ratio of 0.77.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.38 billion. During the same quarter in the previous year, the company earned $0.25 earnings per share. The company’s quarterly revenue was up 9.8% on a year-over-year basis. Analysts forecast that Bausch + Lomb Corporation will post 0.74 earnings per share for the current year.

Institutional Trading of Bausch + Lomb

Institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its position in shares of Bausch + Lomb by 729.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after acquiring an additional 2,042 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares in the last quarter. Wells Fargo & Company MN grew its stake in Bausch + Lomb by 31.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after purchasing an additional 1,403 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Bausch + Lomb by 55.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock worth $132,000 after purchasing an additional 3,246 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Bausch + Lomb during the 3rd quarter worth approximately $170,000. 11.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BLCO has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $18.00 price objective on shares of Bausch + Lomb in a research note on Thursday, February 19th. Wall Street Zen lowered shares of Bausch + Lomb from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Barclays increased their price target on Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. HC Wainwright boosted their price objective on Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Finally, Evercore set a $18.00 target price on Bausch + Lomb and gave the company an “in-line” rating in a research note on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $18.25.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Multiple insiders bought stock last week, signaling management confidence: CEO Brent L. Saunders purchased 14,700 shares (~$252k), CFO Sam Eldessouky bought 4,000 shares (~$68.5k) and EVP A. Robert D. Bailey acquired 14,600 shares (~$250k). These additions raise insider ownership and are typically viewed as a bullish signal for investors. Form 4 — Saunders Form 4 — Eldessouky Form 4 — Bailey
• Positive Sentiment: Short interest declined ~15.9% in February (to ~2.66M shares), lowering the days-to-cover to ~4.5 — a reduction in bearish positioning that can remove a source of selling pressure and support the share price. (Data reported in recent market updates.)
• Positive Sentiment: Bausch + Lomb launched an R&D “Teach‑in” webinar series to walk investors through its differentiated glaucoma pipeline and product roadmap — an investor-focused effort that can increase visibility of growth drivers and reduce uncertainty around the pipeline. Bausch + Lomb Launches R&D “Teach-in” Webinar Series
• Positive Sentiment: Market commentary is focusing on glaucoma-related moves and investor interest in BLCO’s pipeline — increased attention to the glaucoma franchise can be constructive if it translates to higher expectations for future sales and approvals. Bausch And Lomb Glaucoma Moves Catch Market Eyes
• Neutral Sentiment: Analysts and valuation pieces are re‑assessing BLCO following recent revenue growth and lingering net‑loss figures; these analyses can influence medium‑term expectations but are not an immediate directional catalyst. Assessing Bausch + Lomb Valuation

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.